Nasdaq to Amedica: Higher stock price necessary to stay listed — 6 key notes
The Nasdaq Listings Qualifications department sent Amedica a letter saying the minimum bid price per share for its common stock was below $1 for 30 consecutive business days, meaning the company didn't...
View ArticleSpinal tumor surgery with robots — 5 things to know
Can robots help surgeons treat spinal tumors?
View Article6 key updates on Aurora Spine's 1st trache of non-brokered private placement
Aurora Spine completed the first trache of common share non-brokered private placement.
View ArticleAmedica shares see 23% increase
Amedica's stock price rose 23.08 percent last week, although the bid price remains under $1, which could be problematic for the company to remain listed, according to a Winston View report.
View ArticleWhy Carmelo Anthony is down but not out after knee surgery
Orthopedic injuries are a hazard of the job for professional athletes. Yet, most athletes are able to undergo treatment — sometimes surgery — and then return to an elite level of play.
View ArticleACDF vs. posterior cervical foraminotomy reoperation rates — 5 key notes
Both anterior cervical discectomy and fusion and posterior cervical foraminotomy are treatments for patients with cervical radiculopathy with similar outcomes. However, a new study seeks to determine...
View Article5 things to know about Spineology's suit against Wright Medical
Spineology sued Wright Medical Technology, alleging the company's percutaneous expandable reamer infringed on an existing patent, according to a JDSUPRA Business Advisor report.
View ArticleIntegra LifeSciences 2014 revenue up 14.2% — 10 things to know
Integra LifeSciences reported revenue increase in the fourth quarter and full year of 2014, thanks in part to the company's neurosurgery and skin and wound businesses.
View ArticleLDR has 'significantly better growth profile' than others — 5 key concepts
Brean Capital analyst Jason Wittes penned a glowing report on LDR, expecting growth in the future, according to a Benzinga report.
View ArticleFDA advisory panel signals support for VertiFlex's Superion Interspinous...
VertiFlex announced that the FDA's Orthopedic and Rehabilitation Devices Advisory Panel has voted in support of the premarket approval application for its Superion Interspinous Spacer System.
View ArticleThe spine surgeon MBA: Is it necessary to run a good practice?
Business philosophy is important for running a spine practice, but do you need an MBA to get there?
View ArticleCould healthcare reform impact orthopedic trauma care? 5 notes on what...
Massachusetts was among the first states to implement a healthcare overhaul, which became the model for the national Affordable Care Act.
View ArticleGlobus Medical's record year: Sales soar 9.2% — 5 things to know
Globus Medical reported record profits for the fourth quarter and full year in 2014.
View ArticleDrs. Michael Terry, Bradley Merk perform surgery on Chicago Blackhawks'...
Michael Terry, MD, and Bradley Merk, MD, performed surgery on Chicago Blackhawks forward Patrick Kane to repair a broken collarbone, according to a Demanjo report.
View ArticleDr. Alex Etemad joins Healthpointe
Anaheim, Calif.-based Healthpointe added Alex Etemad, MD, to its physician team.
View ArticleDr. Alejandro Betancourt performs Rio Grande Valley's first sacroiliac joint...
Alejandro Betancourt, MD, of Harlingen (Texas) Spine & Neurosurgical Institute, performed Rio Grande Valley's first sacroiliac joint fusion surgery at Valley Baptist Medical Center in Harlingen,...
View ArticleSpine device company stock report: 5 key companies — Feb. 26
Here are the stock reports from five spine device companies for Feb. 26, 2015, including whether the numbers are up or down from last week.
View Article15 spine surgeons making headlines this week — Feb. 27
Here are 15 spine surgeons who were in the news this week.
View ArticleAlphatec Spine sees moderate growth of 1.1% for Q4 & full year — 7 key points
Alphatec Holdings, the parent company of Alphatec Spine, announced financial results for the fourth quarter and full year ended Dec. 31, 2014.
View ArticleNuVasive shares target price raised to $55 by Brean Capital: 4 quick facts
Brean Capital Equities research analysts increased their price objective on NuVasive shares from $53 to $55 in a research note, according to a Dakota Financial News report.
View Article